Gynecological cancers represent more than half of female cancers. It has been clearly established that cancer survivors suffer from important health issues such as pain during sexual intercourse (dyspareunia) and sexual dysfunctions which sorely impact their quality of life. Although it affects more than 63% of cancer survivors, the available treatments remain limited and poorly studied. Cancer survivors are thus confronted with these health issues as well as relationship difficulties and psychological consequences, with limited treatment avenues. Addressing pelvic floor muscle dysfunctions and loss of vaginal elasticity, pelvic floor physiotherapy was shown to be effective in reducing or even alleviating dyspareunia and improving sexual function. Until now, no study investigated this treatment in gynecological cancer survivors with dyspareunia. Therefore, there is a need to examine pelvic floor physiotherapy to determine whether or not gynecological cancer survivors with dyspareunia could benefit from this treatment. The objectives of this single-arm mixed-method study are to evaluate the acceptability and feasibility of a physiotherapy treatment in gynecological cancer survivors suffering from dyspareunia and to explore treatment effects. This single-arm study using mixed methods will involve three data collections (pre- and post-treatment assessments). These assessments will be carried out by physiotherapists. Participants will receive physiotherapy treatment weekly in individual 60-minute sessions for 12 weeks. Thirty-one gynecological cancer survivors with vulvovaginal pain during sexual intercourse for at least 3 months will be recruited. The results of this study will bring new information regarding physiotherapy treatment for this population in preparation for a definitive randomized controlled trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
31
Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Adherence rates
To determine acceptability.
Time frame: Pre- to 2-week post-treatment assessment
Retention rate
To determine feasibility.
Time frame: Pre- to 2-week post-treatment assessment
Change from baseline in pain
To explore changes in pain during sexual intercourse (Numerical Rating Scale, ranging from 0 to 10, where 0 is no pain at all, and 10 is the worst pain ever).
Time frame: Pre- to 2-week post-treatment assessment
Change from baseline in sexual function
To explore changes in sexual function (Female Sexual Function Index).
Time frame: Pre- to 2-week post-treatment assessment
Change from baseline in pelvic floor muscle function
To explore changes in pelvic floor muscle function at rest and during contraction (dynamometry and ultrasound).
Time frame: Pre- to 2-week post-treatment assessment
Change from baseline in quality of life
To explore changes in quality of life (questionnaire).
Time frame: Pre- to 2-week post-treatment assessment
Patient's global impression of change
To determine patient self-reported improvement (Patient's Global Impression of Change).
Time frame: 2-week post-treatment assessment
Adverse events
To document any adverse events.
Time frame: Pre- to 2-week post-treatment assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.